PMVP

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −5%

below

Price vs 50-day avg −1%

below

RSI (14) 53

neutral

MACD trend Positive

52-week position 26%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return +11%

trailing

6-month return +6%

trailing

YTD return −1%

this year

Relative strength −2%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

1 of 69 funds reported for Jun 30 · net -30.8K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

5.38% of float · ▼ -11.9% MoM · 11.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

69 holders — mid 3-yr range

Squeeze score 59

elevated · 0–100

Fundamentals

Weak

EPS growth −30%

Y/Y

Free cash flow $-73.6M

Balance sheet $38.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 70%

annualized · 1-yr

Max drawdown −42%

past year

ATR 5.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Aug 5, 2026 Est · unconfirmed · in 4 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 12, 2026

Technicals

trend & momentum for long-term holders Neutral

0 · 6 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−5% Neutral

Price vs 50-day avg

−1% Neutral

RSI (14)

53 Neutral

MACD trend

Positive Bullish

52-week position

26% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

1 of 69 funds reported for Jun 30 · net -30.8K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

5.38% of float · ▼ -11.9% MoM · 11.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

69 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $1 Now $1 · 26% 52-wk high $2

vs 200-day avg -5% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Median duration of response	8.2	Q1 2026	—
Median time to response	1.3	Q1 2026	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PMVP PMV Pharmaceuticals, Inc. this stock	$67.73M	-0.8%	—	—	5.4%
ONC BeOne Medicines Ltd.	$446.53B	+1.7%	+22179.2%	908.7	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$132.55B	+15.2%	+46.2%	31.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$70.90B	-12.3%	+20.8%	16.5	3.2%
ARGX Argenx SE	$57.49B	+9.4%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 69.4%
Reported: 1 of 69
Top holder: BML Capital Management, L…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

2.9M

Days to cover: 11.3d
Change: -386.1K sh

View

Short Volume

Short vol %

46%

As of: Jul 8, 2026

Short Total

View

Fails to Deliver

FTD shares

2.9K

Value: $4.2K
As of: Apr 27, 2026

View

Off-Exchange

Off-exchange %

56.7%

Week of: May 4, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-77.7M

EPS diluted: $-1.48

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 5, 2026
This year: 6

View

Proposed Sales

Value

$1.5M

Shares: 1.0M
Filed: Oct 23, 2025

View

Earnings & Events

Earnings Calls

Last call

May 12, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
PMVP	-3.9%	+10.7%	+6.0%	-7.5%	-0.8%
SPY	+0.9%	+1.4%	+7.6%	+0.1%	+9.7%
vs SPY	-4.8%	+9.3%	-1.6%	-7.6%	-10.5%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance